Article snapshot taken from[REDACTED] with creative commons attribution-sharealike license.
Give it a read and then ask your questions in the chat.
We can research this topic together.
Technetium (Tc) sulesomab (trade name LeukoScan) is a radio-pharmaceutical composed of anti-human mousemonoclonal antibody that targets the granulocyte associated NCA-90 cell antigen and a conjugated technetium-99mradionuclide. After intravenous administration, Leukoscan enables sensitive and specific whole body measurement of granulocyte infiltration and activation by gamma camera imaging of Tc-antibody bound cells. Total clearance of LeukoScan from blood samples after administration and imaging has been reported at 48 hour time points indicating limited retention of the agent in circulation
It is approved in European markets for the imaging of infections and inflammations in patients with suspected osteomyelitis but has not secured FDA approval for use in American markets. In addition to approved uses, Leukoscan is currently being investigated for other diagnostic purposes like the detection of soft tissue infections, malignant external otitis and prosthetic joint infection. However, the future clinical and investigational use of this agent may be limited as sale of the agent by the parent company Immunomedics was discontinued in 2018.
Gratz S, Reize P, Kemke B, Kampen WU, Luster M, Höffken H (December 2016). "Targeting osteomyelitis with complete besilesomab and fragmented sulesomab antibodies: kinetic evaluations". The Quarterly Journal of Nuclear Medicine and Molecular Imaging. 60 (4): 413–23. PMID25325395.
Vicente AG, Almoguera M, Alonso JC, Heffernan AJ, Gomez A, Contreras PI, Martin-Comin J (December 2004). "Diagnosis of orthopedic infection in clinical practice using Tc-99m sulesomab (antigranulocyte monoclonal antibody fragment Fab'2)". Clinical Nuclear Medicine. 29 (12): 781–5. doi:10.1097/00003072-200412000-00001. PMID15545877. S2CID46580717.
Galletti F, Cammaroto G, Galletti B, Quartuccio N, Di Mauro F, Baldari S (June 2015). "Technetium-99m (mTc)-labelled sulesomab in the management of malignant external otitis: is there any role?". European Archives of Oto-Rhino-Laryngology. 272 (6): 1377–82. doi:10.1007/s00405-014-2938-1. PMID24534898. S2CID25194736.
